

Drug resistance interpretation: PR		HIVDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	L10V <small>97% seen=2,375</small> • I13V <small>99% seen=1,100</small> • G16E <small>98% seen=18,399</small> • R41K <small>99% seen=13,520</small> • R57K <small>99% seen=8,967</small> • L63Q <small>99% seen=1,862</small> • I64V <small>100% seen=1,864</small> • E63D <small>100% seen=1,381</small> • I72IV <small>9-12% seen=6,644</small> • V77I <small>100% seen=1,320</small>	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
fosamprenavir/r (FPV/r)	Susceptible	
indinavir/r (IDV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
nelfinavir (NFV)	Susceptible	
saquinavir/r (SQV/r)	Susceptible	
tipranavir/r (TPV/r)	Susceptible	
PR comments		
Other		
<ul style="list-style-type: none">L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.		

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

NRTI Mutations:	None	
NNRTI Mutations:	None	
RT Other Mutations:	E6D 100% seen=2,628 • K32I 97% seen=2,175 • V35T 100% seen=2,790 • E36D 98% seen=2,367 • V60I 100% seen=3,264 • D121DY 9-10% seen=3,876 • K122KE 9-12% seen=3,329 • D177E 99% seen=3,395 • Q207E 99% seen=3,223 • R211K 99% seen=3,868 • V245QT 1-4% seen=2,769 • P247PQ 1-1% seen=2,362 • E248EDNS 9-10% seen=2,362 • S251SI 9-10% seen=2,125 • A272P 100% seen=2,294 • K281R 99% seen=1,399 • T286A 99% seen=1,395 • E291D 92% seen=1,386 • I293V 100% seen=1,295 • P294T 99% seen=1,294 • S319N 99% seen=1,800 • Q524QH 9-10% seen=1,335 • K527N 99% seen=1,862 • A534S 97% seen=2,534 • A554N 99% seen=2,892	
Nucleoside Reverse Transcriptase Inhibitors		
abacavir (ABC)	Susceptible	
zidovudine (AZT)	Susceptible	
stavudine (D4T)	Susceptible	
didanosine (DDI)	Susceptible	
emtricitabine (FTC)	Susceptible	
lamivudine (3TC)	Susceptible	
tenofovir (TDF)	Susceptible	
Non-nucleoside Reverse Transcriptase Inhibitors		
doravirine (DOR)	Susceptible	
efavirenz (EFV)	Susceptible	
etravirine (ETR)	Susceptible	
nevirapine (NVP)	Susceptible	
rilpivirine (RPV)	Susceptible	

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

INSTI Major Mutations:	None
INSTI Accessory Mutations:	None
IN Other Mutations:	K7R ^{100%} <small>seen=2,790</small> • S17N ^{97%} <small>seen=2,628</small> • V31VI ^{1-10%, G: 27%} <small>seen=2,309</small> • M50L ^{98%} <small>seen=2,338</small> • I72V ^{100%} <small>seen=1,275</small> • T112V ^{100%} <small>seen=1,290</small> • I113V ^{100%} <small>seen=1,261</small> • T124A ^{100%} <small>seen=1,186</small> • T125A ^{99%} <small>seen=1,186</small> • G134D ^{100%} <small>seen=1,692</small> • I182V ^{99%} <small>seen=1,308</small> • V201I ^{99%} <small>seen=2,138</small> • T206S ^{100%} <small>seen=2,280</small> • Y227F ^{100%} <small>seen=2,867</small> • L234V ^{99%} <small>seen=2,588</small> • D253Y ^{99%} <small>seen=1,332</small> • D256E ^{99%} <small>seen=1,302</small> • D279GS ^{G: 80%, G: 14%} <small>seen=2,729</small> • S283SG ^{G: 80%, G: 14%} <small>seen=2,280</small> • R284G ^{99%} <small>seen=2,292</small>
Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

Mutation scoring: IN	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for INSTI.